Tomohide Iwao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomohide Iwao has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Michi Sakai
Department of Health Informatics, Kyoto University School of Medicine and Public Health, Kyoto, Japan, Yoshida Konoe-cho, Sakyo-ku, Kyoto City, Kyoto, Japan, Tel: +81-75-753-9471
3 shared publications - Tomohiro Kuroda
Graduate School of Informatics, Kyoto University, Kyoto, Japan
3 shared publications Genta Kato
Solution Center for Health Insurance Claims, Kyoto University Hospital
2 shared publications- Genta Kato
Solutions Center for Health Insurance Claims, Kyoto University Hospital, Kyoto, Japan
2 shared publications - Shosuke Ohtera
Department of Health Economics, Center for Gerontology and Social Science, Research Institute, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan
2 shared publications Eiji Aramaki
Institute for Research Initiatives Nara Institute of Science and Technology Ikoma Japan
1 shared publication
Latest Publications
- Open Access
- 5 December 2024
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 34 (12) , 600-604
Regional Variation in End-of-life Care Just Before Death Among the Oldest Old in Japan: A Descriptive Study
Background: The use of life-sustaining treatment (LST) in the final stage of life is a major policy concern due to increased costs, while its intensity does not correlate with quality. Previous reports have shown declining trends in LST use in Japan. However, regional practice variations remain unclear. This study aims to describe regional variations in LST use before death among the oldest old in Japan.Methods: A descriptive study was conducted among patients aged 85 or older who passed away between April 2013 and March 2014. The study utilized health insurance claims from Japan's National Database (NDB) to examine the use of cardiopulmonary resuscitation (CPR), mechanical ventilation (MV), and admission to the acute care ward (ACW) in the last 7 days of life.Results: Among 224,391 patients, the proportion of patients receiving LST varied by region. CPR ranged from 8.6% (Chubu) to 12.9% (Shikoku), MV ranged from 7.1% (Chubu) to 12.3% (Shikoku), and admission to ACW ranged from 4.5% (Chubu) to 10.1% (Kyushu-Okinawa). The adjusted odds ratios (AOR) for regional variation compared with Kanto were as follows: CPR (in Shikoku, 1.85 [95% CI 1.73 - 1.98]), MV (in Shikoku, 1.75 [1.63 - 1.87]), and ACW admission (in Kyushu-Okinawa, 1.69 [1.52 - 1.88]).Conclusion: The study presents descriptive information regarding regional differences in the utilization of LST for the oldest old. Further research is necessary to identify the factors that contribute to these variations and to address the challenge of improving the quality of end-of-life care.
- 5 December 2024
- Published by Japan Epidemiological Association in Journal of Epidemiology
- Vol. 34 (12) , 600-604
Open AccessRegional Variation in End-of-life Care Just Before Death Among the Oldest Old in Japan: A Descriptive Study
Background: The use of life-sustaining treatment (LST) in the final stage of life is a major policy concern due to increased costs, while its intensity does not correlate with quality. Previous reports have shown declining trends in LST use in Japan. However, regional practice variations remain unclear. This study aims to describe regional variations in LST use before death among the oldest old in Japan.Methods: A descriptive study was conducted among patients aged 85 or older who passed away between April 2013 and March 2014. The study utilized health insurance claims from Japan's National Database (NDB) to examine the use of cardiopulmonary resuscitation (CPR), mechanical ventilation (MV), and admission to the acute care ward (ACW) in the last 7 days of life.Results: Among 224,391 patients, the proportion of patients receiving LST varied by region. CPR ranged from 8.6% (Chubu) to 12.9% (Shikoku), MV ranged from 7.1% (Chubu) to 12.3% (Shikoku), and admission to ACW ranged from 4.5% (Chubu) to 10.1% (Kyushu-Okinawa). The adjusted odds ratios (AOR) for regional variation compared with Kanto were as follows: CPR (in Shikoku, 1.85 [95% CI 1.73 - 1.98]), MV (in Shikoku, 1.75 [1.63 - 1.87]), and ACW admission (in Kyushu-Okinawa, 1.69 [1.52 - 1.88]).Conclusion: The study presents descriptive information regarding regional differences in the utilization of LST for the oldest old. Further research is necessary to identify the factors that contribute to these variations and to address the challenge of improving the quality of end-of-life care.
- Open Access
- 18 March 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (6) , 3135
Decreased Administration of Life-Sustaining Treatment just before Death among Older Inpatients in Japan: A Time-Trend Analysis from 2012 through 2014 Based on a Nationally Representative Sample
The administration of intensive end-of-life care just before death in older patients has become a major policy concern, as it increases medical costs; however, care intensity does not necessarily indicate quality. This study aimed to describe the temporal trends in the administration of life-sustaining treatments (LSTs) and intensive care unit (ICU) admissions just before death in older inpatients in Japan. We utilized the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Inpatients who were aged ≥65 years and died in October of 2012, 2013, or 2014 were analyzed. The numbers of decedents in 2012, 2013, and 2014 were 3362, 3473, and 3516, respectively. The frequencies of receiving cardiopulmonary resuscitation (CPR) (11.0% to 8.3%), mechanical ventilation (MV) (13.1% to 9.8%), central venous catheter (CVC) insertion (10.6% to 7.8%), and ICU admission (9.1% to 7.8%), declined between 2012 and 2014. After adjusting for age, sex, and type of ward, the declining trends persisted for CPR, MV, and CVC insertion relative to the frequencies in 2012. Our results indicate that the administration of LST just before death in older inpatients in Japan decreased from 2012 to 2014.
- 18 March 2021
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 18 (6) , 3135
Open AccessDecreased Administration of Life-Sustaining Treatment just before Death among Older Inpatients in Japan: A Time-Trend Analysis from 2012 through 2014 Based on a Nationally Representative Sample
The administration of intensive end-of-life care just before death in older patients has become a major policy concern, as it increases medical costs; however, care intensity does not necessarily indicate quality. This study aimed to describe the temporal trends in the administration of life-sustaining treatments (LSTs) and intensive care unit (ICU) admissions just before death in older inpatients in Japan. We utilized the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB). Inpatients who were aged ≥65 years and died in October of 2012, 2013, or 2014 were analyzed. The numbers of decedents in 2012, 2013, and 2014 were 3362, 3473, and 3516, respectively. The frequencies of receiving cardiopulmonary resuscitation (CPR) (11.0% to 8.3%), mechanical ventilation (MV) (13.1% to 9.8%), central venous catheter (CVC) insertion (10.6% to 7.8%), and ICU admission (9.1% to 7.8%), declined between 2012 and 2014. After adjusting for age, sex, and type of ward, the declining trends persisted for CPR, MV, and CVC insertion relative to the frequencies in 2012. Our results indicate that the administration of LST just before death in older inpatients in Japan decreased from 2012 to 2014.
- 25 December 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (4) , 427-432
A survey of clarithromycin monotherapy and long‐term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims
Background: The number of patients with nontuberculous mycobacteriosis (NTM) has increased exponentially in recent years. In Japan, approximately 88.8% of patients with NTM suffer from Mycobacterium avium‐intracellulare complex (MAC) lung disease. Incidence of MAC lung disease is increasing in particularly among the middle‐aged and elderly women owing to a rapid increase in nontuberculous mycobacterial infections.General treatment for MAC lung disease is chemotherapy. The type of chemotherapy recommended by specialists to prevent the development of a drug‐resistant strain of the bacteria consists of a combination of clarithromycin (CAM), rifampicin, and ethambutol (EB). CAM monotherapy is contraindicated by specialists owing to its high potential to induce drug‐resistant bacterial strains in patients with MAC lung disease. In addition, administering EB at doses not less than 1000 mg d−1 is not recommended to avoid adverse drug reactions. However, it is unclear how much such treatment cases exist in real world clinical settings. This is because no long‐term investigation has been carried out.Materials and Methods: This study investigated treatment with these drugs from 2005 to 2017, by studying 1135 patients with MAC lung disease based on health insurance claims database.Results: Results showed that approximately 9.2% (101 cases) were prescribed long‐term CAM monotherapy for 3 months or longer and approximately 3.6% (18 cases) were prescribed high doses of EB.Conclusion: CAM monotherapy over a long period of time is potentially detrimental to some patients. Better awareness of the types of treatments and their potential negative effects will be beneficial to clinical practitioners.
- 25 December 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 29 (4) , 427-432
A survey of clarithromycin monotherapy and long‐term administration of ethambutol for patients with MAC lung disease in Japan: A retrospective cohort study using the database of health insurance claims
Background: The number of patients with nontuberculous mycobacteriosis (NTM) has increased exponentially in recent years. In Japan, approximately 88.8% of patients with NTM suffer from Mycobacterium avium‐intracellulare complex (MAC) lung disease. Incidence of MAC lung disease is increasing in particularly among the middle‐aged and elderly women owing to a rapid increase in nontuberculous mycobacterial infections.General treatment for MAC lung disease is chemotherapy. The type of chemotherapy recommended by specialists to prevent the development of a drug‐resistant strain of the bacteria consists of a combination of clarithromycin (CAM), rifampicin, and ethambutol (EB). CAM monotherapy is contraindicated by specialists owing to its high potential to induce drug‐resistant bacterial strains in patients with MAC lung disease. In addition, administering EB at doses not less than 1000 mg d−1 is not recommended to avoid adverse drug reactions. However, it is unclear how much such treatment cases exist in real world clinical settings. This is because no long‐term investigation has been carried out.Materials and Methods: This study investigated treatment with these drugs from 2005 to 2017, by studying 1135 patients with MAC lung disease based on health insurance claims database.Results: Results showed that approximately 9.2% (101 cases) were prescribed long‐term CAM monotherapy for 3 months or longer and approximately 3.6% (18 cases) were prescribed high doses of EB.Conclusion: CAM monotherapy over a long period of time is potentially detrimental to some patients. Better awareness of the types of treatments and their potential negative effects will be beneficial to clinical practitioners.
- Open Access
- 23 November 2019
- Published by Springer Nature in Environmental Health and Preventive Medicine
- Vol. 24 (1) , 1-6
Validation of claims data to identify death among aged persons utilizing enrollment data from health insurance unions
The identification of death is critical for epidemiological research. Despite recent developments in health insurance claims databases, the quality of death information in claims is not guaranteed because health insurance claims are collected primarily for reimbursement. We aimed to examine the usefulness and limitations of death information in claims data and to examine methods for improving the quality of death information for aged persons.We used health insurance claims data and enrollment data (as the gold standard) from September 2012 through August 2015 for nondependent persons aged 65–74 years enrolled in Japanese workplace health insurance. Overall, 3,710,538 insured persons were registered in the database during the study period. We analyzed 45,441 eligible persons. Inpatient and outpatient deaths were identified from the discharge/disease status in the claims, with sensitivities of 94.3% and 47.4%, specificities of 98.5% and 99.9%, and PPVs of 96.3% and 95.7%, respectively, using enrollment data as the gold standard. For outpatients, death defined as a combination of disease status and charge data for terminal care still indicated low sensitivity (54.7%).The validity of death information in inpatient claims was high, suggesting its potential usefulness for identifying death. However, given the low sensitivity for outpatient deaths, the use of death information obtained solely from records in outpatient claims is not recommended.
- 23 November 2019
- Published by Springer Nature in Environmental Health and Preventive Medicine
- Vol. 24 (1) , 1-6
Open AccessValidation of claims data to identify death among aged persons utilizing enrollment data from health insurance unions
The identification of death is critical for epidemiological research. Despite recent developments in health insurance claims databases, the quality of death information in claims is not guaranteed because health insurance claims are collected primarily for reimbursement. We aimed to examine the usefulness and limitations of death information in claims data and to examine methods for improving the quality of death information for aged persons.We used health insurance claims data and enrollment data (as the gold standard) from September 2012 through August 2015 for nondependent persons aged 65–74 years enrolled in Japanese workplace health insurance. Overall, 3,710,538 insured persons were registered in the database during the study period. We analyzed 45,441 eligible persons. Inpatient and outpatient deaths were identified from the discharge/disease status in the claims, with sensitivities of 94.3% and 47.4%, specificities of 98.5% and 99.9%, and PPVs of 96.3% and 95.7%, respectively, using enrollment data as the gold standard. For outpatients, death defined as a combination of disease status and charge data for terminal care still indicated low sensitivity (54.7%).The validity of death information in inpatient claims was high, suggesting its potential usefulness for identifying death. However, given the low sensitivity for outpatient deaths, the use of death information obtained solely from records in outpatient claims is not recommended.
- 11 November 2019
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 36 (2) , 75-82
Treatment of Mycobacterium avium–intracellulare complex lung disease in the real world: a retrospective big data analysis
- 11 November 2019
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 36 (2) , 75-82
Treatment of Mycobacterium avium–intracellulare complex lung disease in the real world: a retrospective big data analysis
- Open Access
- 1 January 2019
- Published by Longdom Group
- Vol. 08 (01) , 1-4
A Survey of Clarithromycin Monotherapy for Patients with MAC Lung Disease in Japan
Background The number of patients with nontuberculous mycobacteriosis (NTM) has increased exponentially in recent years. In Japan, approximately 88.8% of patients with NTM suffer from Mycobacterium avium-intracellulare complex (MAC) Lung Disease. Incidence of MAC Lung Disease is increasing owing to a rapid increase in nontuberculous mycobacterial infections. Although basic treatment for MAC Lung Disease is chemotherapy, clarithromycin monotherapy is contraindicated by specialists owing to its high potential to induce drug-resistant bacterial strains in patients with MAC Lung Disease. However, it is unclear how much such treatment cases exist in clinical practical. This is because no long-term investigation has been carried out. Materials and Methods This study investigated treatment with these medications from 2005 to 2017, by studying 1107 patients with MAC Lung Disease based on data in patient insurance claims. Results Results showed that approximately 10.3% (114 cases) were prescribed long-term CAM monotherapy for three months. Conclusion Generally, administration of antibiotics over a long period of time is potentially detrimental to some patients. Better awareness of the types of treatments and their potential negative effects will be beneficial to clinical practitioners. In the immediate future, it seems to be effective to develop an educational system on single agent administration of antimicrobial agents.
- 1 January 2019
- Published by Longdom Group
- Vol. 08 (01) , 1-4
Open AccessA Survey of Clarithromycin Monotherapy for Patients with MAC Lung Disease in Japan
Background The number of patients with nontuberculous mycobacteriosis (NTM) has increased exponentially in recent years. In Japan, approximately 88.8% of patients with NTM suffer from Mycobacterium avium-intracellulare complex (MAC) Lung Disease. Incidence of MAC Lung Disease is increasing owing to a rapid increase in nontuberculous mycobacterial infections. Although basic treatment for MAC Lung Disease is chemotherapy, clarithromycin monotherapy is contraindicated by specialists owing to its high potential to induce drug-resistant bacterial strains in patients with MAC Lung Disease. However, it is unclear how much such treatment cases exist in clinical practical. This is because no long-term investigation has been carried out. Materials and Methods This study investigated treatment with these medications from 2005 to 2017, by studying 1107 patients with MAC Lung Disease based on data in patient insurance claims. Results Results showed that approximately 10.3% (114 cases) were prescribed long-term CAM monotherapy for three months. Conclusion Generally, administration of antibiotics over a long period of time is potentially detrimental to some patients. Better awareness of the types of treatments and their potential negative effects will be beneficial to clinical practitioners. In the immediate future, it seems to be effective to develop an educational system on single agent administration of antimicrobial agents.
- Open Access
- 27 September 2018
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 6 (3) , e11021
Extraction and Standardization of Patient Complaints from Electronic Medication Histories for Pharmacovigilance: Natural Language Processing Analysis in Japanese
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Although methods of obtaining knowledge from texts written by healthcare professionals such as electronic medical records and discharge summaries have been studied, there are few reports analyzing free-text data on patients’ complaints in Japanese. Objective: This study aimed to establish a new method for extracting keywords from patients’ free descriptions accumulated in Japanese medical institutions. Methods: We developed a system that automatically annotates free-text data with the codes of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) using electronic medication history data (target period: September 1, 2015 to August 31, 2016). The performance of the system was evaluated through comparisons with data manually annotated by healthcare workers. Results: The number of ICD10 codes extracted from 5,000 patient statements by healthcare workers was 2,348, while the system extracted 2,236 codes. Of those cases, 1,480 matched. Compared with manual extraction, the performance of the system was 0.66 in terms of precision, 0.63 in recall, and 0.65 for the F-measure. Conclusions: Our results suggested that the system was helpful for extracting and standardizing patient’s words related to symptoms from massive amounts of free-text data instead of manual work. After improving the extraction accuracy, we expect to utilize this system to detect the signals of adverse drug reactions from patients’ statements in the future.
- 27 September 2018
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 6 (3) , e11021
Open AccessExtraction and Standardization of Patient Complaints from Electronic Medication Histories for Pharmacovigilance: Natural Language Processing Analysis in Japanese
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Although methods of obtaining knowledge from texts written by healthcare professionals such as electronic medical records and discharge summaries have been studied, there are few reports analyzing free-text data on patients’ complaints in Japanese. Objective: This study aimed to establish a new method for extracting keywords from patients’ free descriptions accumulated in Japanese medical institutions. Methods: We developed a system that automatically annotates free-text data with the codes of the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD10) using electronic medication history data (target period: September 1, 2015 to August 31, 2016). The performance of the system was evaluated through comparisons with data manually annotated by healthcare workers. Results: The number of ICD10 codes extracted from 5,000 patient statements by healthcare workers was 2,348, while the system extracted 2,236 codes. Of those cases, 1,480 matched. Compared with manual extraction, the performance of the system was 0.66 in terms of precision, 0.63 in recall, and 0.65 for the F-measure. Conclusions: Our results suggested that the system was helpful for extracting and standardizing patient’s words related to symptoms from massive amounts of free-text data instead of manual work. After improving the extraction accuracy, we expect to utilize this system to detect the signals of adverse drug reactions from patients’ statements in the future.
- 20 September 2018
- Published by Japanese Society for Pharmacoepidemiology in Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku
- Vol. 23 (2) , 89-94
Survey of Drug Prescription Patterns Among Patients with Nontuberculous Mycobacterial Disease Using the Database of Health Insurance Claims
近年,非結核性抗酸菌症の罹患者が急激に増加している.罹患者数は 2014 年に実施された全国調査によると,1980 年の調査時と比較して約 9.7 倍となったことが報告された.この中で,約 88.8 %を肺 MAC 症が占めている.肺 MAC 症は,中高年の女性を中心として増加しており非結核性抗酸菌症の急激な増加の要因となっている.肺 MAC 症の治療は,菌陰性化から 1 年以上に渡る化学療法が一般的である.専門家の間では,クラリスロマイシン(以下,CAM),リファンピシン,エタンブトール(以下,EB)を併用することで,耐性菌の発生を防ぐ化学療法が推奨されている.一方で,非結核性抗酸菌症患者に対する CAM の単剤投与は,耐性菌誘発の可能性が高いことから,専門家の間では原則禁忌とされている.また同様に,750 mg 超/日の EB 高用量投与も副作用の影響から推奨されていない.しかしながら,臨床現場において上記のような処方事例がどの程度存在するかについては,これまで広範な調査はなされていないため,その実態は不明であった.そこで本研究では,健康保険組合に加入している被保険者レセプトのうち,2015 年から 2016 年の 2 年間で非結核性抗酸菌症患者と推定される 571 人を解析対象とし,薬剤処方実態を調査した.その結果,3 カ月以上の長期間に渡る CAM 単剤処方が約 5.1 % (29 件),EB の高用量処方が EB 処方の 338 件中約 4.4 % (15 件) の割合でみられた.一般に,非結核性抗酸菌症は長期間の抗生剤投与が必要となるため,一部の患者は不利益を被る可能性がある.今後は,臨床現場に正しい情報を広く周知することが喫緊の課題であると考える.
- 20 September 2018
- Published by Japanese Society for Pharmacoepidemiology in Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku
- Vol. 23 (2) , 89-94
Survey of Drug Prescription Patterns Among Patients with Nontuberculous Mycobacterial Disease Using the Database of Health Insurance Claims
近年,非結核性抗酸菌症の罹患者が急激に増加している.罹患者数は 2014 年に実施された全国調査によると,1980 年の調査時と比較して約 9.7 倍となったことが報告された.この中で,約 88.8 %を肺 MAC 症が占めている.肺 MAC 症は,中高年の女性を中心として増加しており非結核性抗酸菌症の急激な増加の要因となっている.肺 MAC 症の治療は,菌陰性化から 1 年以上に渡る化学療法が一般的である.専門家の間では,クラリスロマイシン(以下,CAM),リファンピシン,エタンブトール(以下,EB)を併用することで,耐性菌の発生を防ぐ化学療法が推奨されている.一方で,非結核性抗酸菌症患者に対する CAM の単剤投与は,耐性菌誘発の可能性が高いことから,専門家の間では原則禁忌とされている.また同様に,750 mg 超/日の EB 高用量投与も副作用の影響から推奨されていない.しかしながら,臨床現場において上記のような処方事例がどの程度存在するかについては,これまで広範な調査はなされていないため,その実態は不明であった.そこで本研究では,健康保険組合に加入している被保険者レセプトのうち,2015 年から 2016 年の 2 年間で非結核性抗酸菌症患者と推定される 571 人を解析対象とし,薬剤処方実態を調査した.その結果,3 カ月以上の長期間に渡る CAM 単剤処方が約 5.1 % (29 件),EB の高用量処方が EB 処方の 338 件中約 4.4 % (15 件) の割合でみられた.一般に,非結核性抗酸菌症は長期間の抗生剤投与が必要となるため,一部の患者は不利益を被る可能性がある.今後は,臨床現場に正しい情報を広く周知することが喫緊の課題であると考える.